Clinical Research Directory

Inclusion Criteria: 1. Patients with ventricular dilatation due to intraventricular hemorrhage who clinically present with any one or more of new gait disturbances, cognitive deficits, and urinary incontinence after remission of intraventricular hemorrhage symptoms, and whose brain imaging shows an Evans index (EI) of ≥0.3 2. Age ≥ 18 years and ≤ 70 years 3. Signed informed consent form Exclusion Criteria: 1. Participation in another medical trial 2. Have other disease that may affect the patient's symptoms (including gait disturbance, cognitive impairment, urinary incontinence) 3. Allergy to the investigational drug 4. Reduced liver function (increased INR or alanine transaminase concentrations in plasma elevated more than 1.5 times reference values) 5. Reduced kidney function with GFR \< 50 6. Concomitant treatment with strong CYP3A4/5 inducers or inhibitors, such as diltiazem, ketoconazole, or rifampicin. 7. Active or uncontrolled chronic infection 8. Women who are pregnant or breastfeeding 9. Patients who are bedridden or require urinary catheters for extended periods of time.